科技科学

China should share the evidence behind animal-testing alternatives openly

Nature查看原文 ↗
  • CORRESPONDENCE

By

  • Shuhang Wang1 &
  • Ning Li2
  1. Guo Zhao

    1. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

  2. Shuhang Wang

    1. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

  3. Ning Li

    1. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

China’s PIONEER pilot, implemented in September, promotes fresh approaches to drug testing, including human tissue models and computer simulations. It promises to publish lists of validated methods, case studies and key technical points. Its next step should be to make the evidence behind regulatory decisions open to scrutiny.

Nature 659, 264 (2026)

doi: https://doi.org/10.1038/d41586-026-03561-7

Competing Interests

The authors declare no competing interests.

Subjects

Latest on:

  • Drug discovery
  • Medical research
  • Policy

  • Making ‘mind pictures’ takes mental effort

    News & Views

  • Will this sleep-disorder drug be the next big blockbuster?

    News Feature

  • Unprecedented atlas explores mitochondria across the tree of life

    News

  • This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?

    News Feature

  • How personalization and psychedelics are revitalizing psychiatry

    Editorial

  • Gene therapy that led to boy’s death had limited efficacy

    News

  • Will AI grant reviews make science more conservative?

    Nature Index

  • Trump’s executive order on women’s health feels like déjà vu

    World View

  • How democracy depends on science — and must protect it

    Comment